NEW BIOMARKERS AS PUTATIVE PREDICTORS OF BREAST CANCER PROGRESSION

SCIACCA M; CARBALLO MP; LACUNZA E; MARINO L; ROCA MF; ABBA MC; ROJAS BILBAO E; EIJAN AM; LODILLINSKY C

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Ductal carcinoma in situ (DCIS) in breast cancer is defined as a proliferation of epithelial neoplastic cells contained within the lumen of mammary ducts (Cowell, 2013). Currently, evidence suggests that in situ tumors are precursors of invasive tumors, but progression markers are not yet available. By using an intraductal xenograft model, we demonstrated that membrane-type 1 matrix metalloproteinase (MT1-MMP) is essential for the transition from in situ to invasivetumors (Lodillinsky, 2016; 2021). Subsequently, we completed an RNAseq analysis (Illumina HISeqTM, p